Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts on Utility of clonoSEQ® in MRD Testing in Blood Cancer Patients at the 63rd ASH Annual Meeting
02 déc. 2021 08h00 HE
|
Adaptive Biotechnologies
SEATTLE, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting
04 nov. 2021 16h15 HE
|
Aprea Therapeutics
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021
04 nov. 2021 09h17 HE
|
Imara, Inc.
Tovinontrine (IMR-687) VOC data in patients with sickle cell disease from ongoing Phase 2a open-label extension study and preclinical models of beta-thalassemia to be presented Oral presentation...
Sana Biotechnology to Present Pre-Clinical Data at 2021 American Society of Hematology Annual Meeting
04 nov. 2021 09h07 HE
|
Sana Biotechnology, Inc
SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be...
Immunicum presenterar uppdaterade resultat för Fas II ADVANCE II vid Annual American Society of Hematology Meeting (ASH)
04 nov. 2021 09h02 HE
|
Immunicum AB
Pressmeddelande 4 november 2021 Immunicum presenterar uppdaterade resultat för Fas II ADVANCE II vid Annual American Society of Hematology Meeting (ASH) Immunicum AB (publ; IMMU.ST), ett...
Immunicum to Present Data Update on Phase II ADVANCE II at Annual American Society of Hematology Meeting (ASH)
04 nov. 2021 09h02 HE
|
Immunicum AB
Press Release November 4, 2021 Immunicum to Present Data Update on Phase II ADVANCE II at Annual American Society of Hematology Meeting (ASH) Immunicum AB (publ; IMMU.ST), a biopharmaceutical...
MacroGenics Presents Tebotelimab Data in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma at the 2020 ASH Annual Meeting
07 déc. 2020 07h30 HE
|
MacroGenics, Inc.
53.8% ORR in relapsed/refractory DLBCL patients Preliminary duration of response of up to 168 days observed, with six of seven ongoing responses as of cut-off date ROCKVILLE, MD, Dec. 07,...
Aptose Presents Highlights from ASH and Corporate Update Event
06 déc. 2020 17h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, December...
MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
06 déc. 2020 13h00 HE
|
MacroGenics, Inc.
31.8% CR/CRh/CRi rate in primary induction failure and early relapsed AML patientsMedian duration of response = 8.13 months ROCKVILLE, MD, Dec. 06, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc....
Cellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL at American Society of Hematology (ASH) Annual Meeting
05 déc. 2020 17h00 HE
|
Cellectis Inc.
Cellectis’ Proprietary Program UCART22 was Safely Administered in BALLI-01 Phase 1 Study with No Dose-Limiting Toxicity or Evidence of Graft-Vs-Host Disease 2 out of 3 Patients at DL1 Achieved...